ArticleAnnals of translational medicine2021

The integration of bevacizumab improves tumor response and survival in patients with refractory cervical cancer treated with radical chemoradiotherapy.

Hua Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.